World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 6 January 2025
Main ID:  NCT02500381
Date of registration: 14/07/2015
Prospective Registration: Yes
Primary sponsor: Sarepta Therapeutics, Inc.
Public title: Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) ESSENCE
Scientific title: A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Date of first enrolment: September 28, 2016
Target sample size: 228
Recruitment status: Active, not recruiting
URL:  https://clinicaltrials.gov/ct2/show/NCT02500381
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).  
Phase:  Phase 3
Countries of recruitment
Argentina Australia Belgium Bulgaria Canada Czechia Denmark France
Germany Greece Hungary India Ireland Israel Italy Korea, Republic of
Mexico Poland Russian Federation Serbia Spain Sweden United Kingdom United States
Contacts
Name:     Medical Director
Address: 
Telephone:
Email:
Affiliation:  Sarepta Therapeutics, Inc.
Key inclusion & exclusion criteria
Inclusion Criteria:

- Genotypically confirmed DMD, with genetic deletion amenable to exon 45 or exon 53
skipping

- Stable dose of oral corticosteroids for at least 24 weeks prior to Week 1, and the
dose is expected to remain constant throughout the study (except for modifications
to accommodate changes in weight).

- Intact right and left biceps brachii muscles or 2 alternative upper arm muscle
groups

- Mean 6MWT =300 meters and =450 meters

- Stable pulmonary function: forced vital capacity (FVC) =50% predicted

Exclusion Criteria:

- Treatment with gene therapy at any time

- Previous treatment with SMT C1100 within 1 week prior to Week 1 and previous
treatment with PRO045 (BMN 045), PRO053 (BMN 053), or PRO051 (BMN 051) within 24
weeks prior to Week 1

- Current or previous treatment with any other experimental treatment within 12 weeks
prior to Week 1

- Major surgery within 3 months prior to Week 1

- Presence of other clinically significant illness

- Other inclusion/exclusion criteria may apply.



Age minimum: 6 Years
Age maximum: 13 Years
Gender: Male
Health Condition(s) or Problem(s) studied
Duchenne Muscular Dystrophy
Intervention(s)
Drug: SRP-4045
Drug: SRP-4053
Drug: Placebo
Primary Outcome(s)
Change From Baseline in the 4-Step Ascend Velocity at Week 96 [Time Frame: Baseline, Week 96]
Secondary Outcome(s)
Change from Baseline in Rise from Floor Velocity at Week 96 [Time Frame: Baseline, Week 96]
Change From Baseline in Total Distance Walked During the 10-meter walk/run (10-MWR) Velocity [Time Frame: Baseline, Week 96]
Change From Baseline in the 4-Step Ascend Velocity at Week 144 [Time Frame: Baseline, Week 144]
Change from Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Weeks 48 or 96 [Time Frame: Baseline, Week 48 or Week 96]
Change from Baseline in Dystrophin Protein Levels Determined by Western Blot at Weeks 48 or 96 [Time Frame: Baseline, Week 48 or Week 96]
Change from Baseline in the Total Distance Walked During 6MWT at Week 96 [Time Frame: Baseline, Week 96]
Change From Baseline in the North Star Ambulatory Assessment (NSAA) Total Score at Week 96 [Time Frame: Baseline, Week 96]
Secondary ID(s)
2024-514698-23-00
4045-301
2015-002069-52
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey